Immune Support Stack

Thymosin Alpha 1 (Tα1, CAS 62304-98-7, molecular weight 3108 Da) is a 28-amino-acid acetylated peptide naturally produced by the thymus gland, approved in 35 countries under the brand name Zadaxin. The US restricted it from compounding pharmacies, creating a regulatory contradiction that defines its story. It binds Toll-like receptors TLR2 and TLR9 on dendritic cells, triggering downstream T-cell differentiation and NK cell activation through MyD88-dependent signaling. The clinical dose is 1.6 mg (1600 mcg) subcutaneously twice weekly, established by decades of Zadaxin prescribing data. The hepatitis B trials built the evidence base. A Phase III RCT (PMC4688733) showed HBeAg seroconversion at 30 to 40% versus 18% on placebo at 12 months. The Dinetz and Lee 2024 review (PMID 38308608) pulled together 30+ trials enrolling 11,000+ subjects and found consistent immune activation across indications. A separate 2024 meta-analysis (PMID 39648386) of 39 RCTs in acute COPD exacerbations (3,329 patients) confirmed improved FEV1, oxygenation, and reduced hospital stay. Community use has expanded well past hepatitis. Longevity practitioners, long COVID patients, and ME/CFS communities use the same 1600 mcg twice-weekly protocol for T-cell restoration. The practical limitation: Tα1 produces no subjective "feel." Bloodwork (CBC with differential, CD4/CD8 ratio) is the only way to confirm it's working. The TESTS Phase 3 sepsis trial (PMID 39814420, n=1,106) missed its primary mortality endpoint (HR 0.99, p=0.93). That null result is worth knowing. It didn't undermine the hepatitis or immune-support evidence, but it set a boundary on what Tα1 can do in acute critical care.

KPV (Lysine-Proline-Valine, CAS 67727-97-3) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone and one of the most discussed anti-inflammatory peptides in the gut health community. It doesn't bind melanocortin receptors the way full-length alpha-MSH does. Instead, it enters cells through PepT1, a di/tripeptide transporter expressed in the small intestine. The targeting gets interesting during active inflammation. PepT1 expression increases in inflamed colonic epithelium, confirmed in both Caco2-BBE cell lines and mouse colitis models (Dalmasso et al., Gastroenterology 2008, PMID 18061177). Inflamed tissue absorbs more KPV than healthy tissue. Once inside the cell, KPV inhibits NF-kB nuclear translocation at nanomolar concentrations, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8. Community use mirrors the preclinical rationale almost exactly. Oral dosing at 500 to 1,500 mcg per day on an empty stomach is the standard protocol for IBD, IBS, and leaky gut. Subcutaneous injection at 200 to 500 mcg per day covers systemic inflammation. The BPC-157 stack is the most discussed combination; KPV handles the inflammatory signaling while BPC-157 drives mucosal repair. Multiple integrative medicine clinics recommend this pairing. The honest limitation: every dose recommendation comes from mouse data extrapolation and community trial-and-error. No human pharmacokinetic study has measured oral bioavailability. No dose-finding trial has been completed. The plasma half-life (~30 minutes) is estimated from alpha-MSH family kinetics, not from direct KPV measurement. Fifteen PubMed papers cover this peptide. The FDA has stated it lacks human exposure data for any administration route. That gap between clean preclinical science and absent human validation defines where KPV sits right now.

Interaction Warnings